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Purpose: Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune disease. The monocyte chemoattractant protein-1
(MCP-1) gene has been implicated in the pathogenesis of certain autoimmune diseases. The aim of this study was to
examine whether a MCP-1 polymorphism was associated with VKH syndrome.
Methods: A case-control analysis was performed using genomic DNA samples from 307 VKH patients and 319 age-,
sex-, and ethnically-matched healthy controls. The MCP-1 polymorphism at the −2518 A/G locus was genotyped using
polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay.
Results: The distribution of genotypic frequency of the MCP-1 −2518 A/G polymorphism in all subjects did not deviate
from Hardy–Weinberg equilibrium (HWE; p>0.05). Allelic and genotypic frequency analysis revealed no significant
difference between VKH patients and healthy controls for the MCP-1 −2518 A/G polymorphism (p>0.05). No significant
differences were found according to gender and neither was found according to extraocular findings including neck
stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo.
Conclusions: The result suggests that the susceptibility to VKH syndrome in Chinese Han patients may be not influenced
by the MCP-1 −2518 A/G polymorphism.
Vogt-Koyanagi-Harada   (VKH)  syndrome   is   a
multisystem disorder mainly affecting pigmented tissues in
the eye, auditory, integumentary, and central nervous systems.
The  clinical  features  of  VKH  syndrome  include  bilateral
granulomatous  panuveitis  frequently  associated  with
extraocular  findings  including  pleocytosis  in  the
cerebrospinal fluid (CSF), dysacusis, alopecia, poliosis, and
vitiligo [1-3]. Although the etiology and pathogenesis of VKH
syndrome remain unclear, numerous studies have suggested
that  this  syndrome  is  considered  to  be  a  cell-mediated
autoimmune  disease  directed  against  melanocytes.
Epidemiological studies show that VKH syndrome is more
prevalent in certain racial and ethnic groups, particularly in
pigmented  groups  [3]  such  as  Asian  and  Latin-American
populations and displays an adventive familial aggregation
pattern  [4].  Two  human  leukocyte  antigen  (HLA)  genes,
HLA-DR4  and  HLA-DRw53,  have  been  shown  to  be
associated  with  VKH  patients  in  various  ethnic  groups
including the Chinese and Japanese [5-7]. These evidences
suggest that immune-associated genetic factors may play a
crucial role in the pathogenesis of VKH syndrome. However,
the previously reported genetic risks for VKH syndrome such
as  HLA-DR4  and  HLA-DRw53  account  for  only  a  small
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portion  of  the  overall  estimated  risk  for  this  syndrome,
suggesting  that  non-HLA  genes  may  confer  a  substantial
proportion  of  genetic  susceptibility  to  this  syndrome.
Therefore,  studies  on  the  disease  association  with  genes
involved in the immune response may highlight the genetic
susceptibility to VKH syndrome.
MCP-1 is a potent chemokine released by lymphocyte,
monocytes, mast cells, and eosinophils during inflammation
and also produced by ocular cells such as the retinal pigment
epithelial cell cultured in vitro [8]. MCP-1 has been implicated
in the recruitment of leukocytes into the site of inflammation.
The elevated MCP-1 concentration in the aqueous humor of
active anterior uveitis patients [9] and ocular fluids and tissues
during ocular inflammation [9-13] combined with the recent
reports  showing  an  association  of  MCP-1  −2518  A/G
polymorphism with uveitis [14-16] and multiple autoimmune
diseases [17-19] suggest that MCP-1 may be involved in the
pathogenesis  of  VKH  syndrome.  The  present  study  was
therefore designed to examine the association of the MCP-1
−2518 A/G polymorphism with VKH syndrome using a case–
control association study.
METHODS
Subjects: This study was approved by the ethics committees
of our hospitals and adhered to the tenets of the Declaration
of  Helsinki.  Additionally,  informed  consent  was  obtained
from each participant or each participant’s guardian. After
giving informed consent, blood samples were collected from
307  Chinese  Han  VKH  patients  and  319  age-  and  sex-
Molecular Vision 2009; 15:1537-1541 <http://www.molvis.org/molvis/v15/a164>
Received 8 July 2009 | Accepted 5 August 2009 | Published 8 August 2009
© 2009 Molecular Vision
1537matched,  unrelated,  healthy  Chinese  Han  controls,  which
were recruited from Zhongshan Ophthalmic Center, Sun Yat-
sen  University  (Guangzhou,  P.R.  China)  and  the  First
Affiliated     Hospital,    Chongqing     Medical     University
(Chongqing, P.R. China) from April 2005 to March 2009. All
VKH patients were diagnosed according to the revised criteria
for VKH syndrome [20].
DNA  extraction:  Genomic  DNA  was  prepared  from
peripheral  blood  mononuclear  cells  (PBMCs)  of  VKH
patients and healthy controls using the QIAamp DNA Mini
Blood  Kit  (Qiagen,  Hilden,  Germany)  according  to
manufacturer’s instructions. DNA samples were collected in
a 1.5 ml Eppendorf tube and stored at −20 °C until use.
Genotyping:  Genotyping  for  the  MCP-1  polymorphism
(−2518A/G, rs1024611 in dbSNP database) was performed
using polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP). The forward primer, 5′-CCG
CAT TCA ATT TCC CTT TAT-3′, and reverse primer, 5′-
TTC CAA AGC TGC CTC CTC A-3′, were designed using
primer premier 5.0 software (Premier Biosoft International,
Palo Alto, CA). PCR reactions were performed under the
following conditions: 10 min at 94 °C followed by 35 cycles
at 95 °C for 45 s, 55 °C for 45 s, 72 °C for 45 s, and then for
3 min at 72 °C. The PCR products were incubated with PvuII
at 37 °C (New England Biolabs Inc., Ontario, Canada) for at
least 3 h and separated on 2% agarose gels. Ten percent of the
PCR  samples  were  directly  sequenced  to  confirm  the
polymerase  chain  reaction  restriction  fragment  length
polymorphism  (PCR-RFLP)  results  (Invitrogen
Biotechnology Co., Shanghai, P.R. China).
Statistical analysis: Statistical analysis was performed with
the SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL).
Hardy–Weinberg Equilibrium (HWE) was tested by the χ2
test. We evaluated the frequency of genotypes and alleles in
this study using the χ2 test. All statistical tests were two-sided,
and statistical significance was taken when p<0.05.
RESULTS
Clinical  findings  of  VKH  patients  and  characteristics  of
controls are presented in Table 1. The mean age of VKH
patients was 34.3±10.3 years and that of healthy controls was
34.7±11.6 years (Table 1). There was no significant difference
in the distribution of age between VKH patients and controls
(p>0.05).
Three hundred and seven VKH patients and 319 healthy
controls  were  genotyped  for  the  MCP-1  −2518  A/G
polymorphism. The result of genotyping was matched with
that  of  direct  sequencing  for  10%  of  the  samples.  The
distribution of genotypic frequency of this single nucleotide
polymorphism (SNP) in all subjects did not show a significant
deviation  from  Hardy–Weinberg  equilibrium  (HWE;
p>0.05).
The distributions of genotypic and allelic frequencies of
the MCP-1 −2518 A/G polymorphism are shown in Table 2.
No  genetic  association  was  demonstrated  between  the
−2518A/G polymorphism of MCP-1 and VKH syndrome in
TABLE 1. CLINICAL FINDINGS OF PATIENTS WITH VKH SYNDROME.
Clinical findings
VKH Patients
Total (n=307) %
Age at onset (years±SD) 34.3±10.3
Male/Female 171/136
Neck stiffness 136 44.3%
Alopecia 109 35.5%
Poliosis 96 31.3%
Vitiligo 48 15.6%
Dysacusia 73 23.8%
Tinnitus 117 38.1%
Scalp hypersensitivity 48 15.6%
This table summarizes the clinical findings of VKH patients.
TABLE 2. FREQUENCIES OF ALLELES AND GENOTYPES OF MCP-1 POLYMORPHISM IN VKH PATIENTS AND CONTROLS.
SNP
Genotype/
Allele VKH (n=307) Controls (n=319) χ2 p value OR (95% CI)
MCP-1 −2518 A/G AA 76 (24.8%) 89 (27.9%) 0.797 0.372 0.85 (0.60–1.21)
AG 152 (49.5%) 135 (42.3%) 3.259 0.071 1.34 (0.98–1.83)
GG 79 (25.7%) 95 (29.8%) 1.277 0.258 0.82 (0.58–1.16)
A 304 (49.5%) 313 (49.1%) 0.026 0.873 1.02 (0.82–1.27)
G 310 (50.5%) 325 (50.9%) 0.026 0.873 0.98 (0.79–1.23)
The genotypic and allelic frequencies of MCP-1 -2518 A/G polymorphism were compared between patients and controls. No
significant differences of the genotypic and allelic frequencies were found betweeen VKH patients and controls.
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in the immune diseases suggest its possible involvement in the
development of VKH syndrome. In addition, our results did
not  indicate  a  significant  difference  when  allelic  and
genotypic  frequencies  of  the  MCP-1  −2518  A/G
polymorphism were analyzed according to gender and any
one of extraocular findings including neck stiffness, tinnitus,
alopecia,  poliosis,  dysacusia,  scalp  hypersensitivity,  and
vitiligo.
DISCUSSION
The present study was to investigate the association of the
MCP-1 polymorphism with VKH syndrome in the Chinese
Han  population.  The  results  showed  that  there  was  no
association  between  the  MCP-1  polymorphism  and  VKH
syndrome. The stratification analysis according to gender or
extraocular findings did not show any association.
VKH syndrome is a multifactorial autoimmune disease
that may result from interactions between susceptibility genes
and  environmental  factors.  Several  studies  have  been
performed to investigate the genetic risk for VKH syndrome.
Recently,  we  reported  two  susceptible  genes  to  VKH
syndrome  including  cytotoxic  T  lymphocyte-associated
antigen-4 (CTLA-4) and programmed cell death 1 (PDCD1)
in the Chinese population [21,22]. Horie and coworkers [23,
24] showed a lack of association of the tyrosinase gene family
(TYR,  TYRP1,  and  DCT)  and  interferon-γ  with  VKH
syndrome  in  Japanese  patients.  In  this  study,  we  tested
whether the −2518 A/G polymorphism of MCP-1, a crucial
chemokine, was associated with Chinese Han VKH patients.
As a case–control association study may be influenced by
various  factors  including  population  composition  and
stratification, the present study drew up the following attempts
to ensure the analysis results. First, the controls and patients
were strictly matched according to the place where they were
born to exclude the possible influence of stratification of the
population.  Individuals  with  any  autoimmune  disease  and
ocular  inflammation  were  excluded  from  the  controls  by
careful  inquiry  of  history  and,  if  necessary,  by  relevant
examinations. Second, we restricted our study population to
Chinese  Han  descent  to  minimize  confounding  by  ethnic
variation. Third, the number of donors enrolled in this study
(307 VKH patients and 319 age-, sex-, ethnically-matched
healthy controls) was large enough to avoid a bias of the
results. Finally, direct sequencing for 10% of the samples was
performed to validate the result of genotyping.
Several studies have been focused on the association of
the  MCP-1  −2518  A/G  polymorphism  with  certain
autoimmune  diseases  [15,25,26].  The  investigated
polymorphism, which is located in the promoter region of
MCP-1, has been shown to affect the transcriptional activation
of this gene [19]. Therefore, this polymorphism is considered
a good candidate in the genetic predisposition to autoimmune
diseases. Thus, we focused our study on the association of this
polymorphism  with  VKH  syndrome.  Unexpectedly,  no
association  was  found  in  these  VKH  patients.  As  VKH
syndrome is a multisystem disorder characterized by ocular
and various extraocular findings, we further performed an
association study of the MCP-1 polymorphism with these
extraocular  findings.  Similarly,  we  did  not  find  any
association  of  this  polymorphism  with  any  one  of  these
clinical  findings.  This  result  is  consistent  with  the  recent
reports,  which  demonstrated  a  lack  of  association  of  the
MCP-1 −2518 A/G polymorphism with multiple sclerosis
(MS)  and  ulcerative  colitis  (UC)  [27].  Contrary  to  our
observation, this polymorphism was found to be significantly
associated  with  rheumatic  arthritis  (RA),  systemic  lupus
erythematosus (SLE), and juvenile rheumatoid arthritis (JRA)
[25,28,29]. Taken together, these data suggest that the MCP-1
−2518 A/G polymorphism may play a role in certain but not
all autoimmune diseases.
Likewise  with  other  candidate  gene  studies,  several
possible limitations exist in our study. A complex multigenic
disease  involves  the  interaction  of  various  genetic  and
environmental factors. Therefore, it is unlikely that any single
gene has an exclusive effect on the development of VKH
syndrome. The present study only examined the association
of the MCP-1 polymorphism with VKH syndrome but did not
refer to the association study of the other susceptible genes.
Furthermore, the tested polymorphism in this study is only
one  of  the  polymorphisms  of  MCP-1.  It  is  necessary  to
examine all the tag SNPs of MCP-1 to understand the precise
association of MCP-1 with VKH syndrome. In addition, the
patients enrolled in this study were recruited from Chinese
Han individuals, and so the results presented here need to be
confirmed using different ethnic populations.
In summary, the present study suggests that there was no
association between the MCP-1 −2518 A/G polymorphism
and VKH syndrome. This result remained in stratification
analysis according to the gender and various clinical findings.
ACKNOWLEDGMENTS
This work was supported by Key Project of Natural Science
Foundation (30630064), National Supporting Project of P.R.
China, Key Project of Health Bureau of Chongqing (2008–
1-15),  Key  Project  of  Natural  Science  Foundation  of
Chongqing (CSTC, 2009BA5037), and Project of Chongqing
Key Laboratory of Ophthalmology (CSTC, 2008CA5003).
The authors would also like to thank all donors enrolled in the
present study.
REFERENCES
1. Moorthy  RS,  Inomata  H,  Rao  NA.  Vogt-Koyanagi-Harada
syndrome.  Surv  Ophthalmol  1995;  39:265-92.  [PMID:
7725227]
2. Forster DJ, Cano MR, Green RL, Rao NA. Echographic features
of the Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol
1990; 108:1421-6. [PMID: 2222275]
Molecular Vision 2009; 15:1537-1541 <http://www.molvis.org/molvis/v15/a164> © 2009 Molecular Vision
15393. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical
characteristics  of  Vogt-Koyanagi-Harada  syndrome  in
Chinese patients. Ophthalmology 2007; 114:606-14. [PMID:
17123618]
4. Rutzen  AR,  Ortega-Larrocea  G,  Schwab  IR,  Rao  NA.
Simultaneous onset of Vogt-Koyanagi-Harada syndrome in
monozygotic  twins.  Am  J  Ophthalmol  1995;  119:239-40.
[PMID: 7832237]
5. Zhao M, Jiang Y, Abrahams IW. Association of HLA antigens
with  Vogt-Koyanagi-Harada  syndrome  in  a  Han  Chinese
population.  Arch  Ophthalmol  1991;  109:368-70.  [PMID:
2003797]
6. Zhang  XY,  Wang  XM,  Hu  TS.  Profiling  human  leukocyte
antigens  in  Vogt-Koyanagi-Harada  syndrome.  Am  J
Ophthalmol 1992; 113:567-72. [PMID: 1575232]
7. Islam SM, Numaga J, Fujino Y, Hirata R, Matsuki K, Maeda
H, Masuda K. HLA class II genes in Vogt-Koyanagi-Harada
disease. Invest Ophthalmol Vis Sci 1994; 35:3890-6. [PMID:
7928186]
8. Holtkamp GM, De Vos AF, Peek R, Kijlsta A. Analysis of the
secretion pattern of monocyte chemotactic protein-1 (MCP-1)
and transforming growth factor-beta 2 (TGF-beta2) by human
retinal  pigment  epithelial  cells.  Clin  Exp  Immunol  1999;
118:35-40. [PMID: 10540157]
9. Verma MJ, Lloyd A, Rager H, Strieter R, Kunkel S, Taub D,
Wakefield D. Chemokines in acute anterior uveitis. Curr Eye
Res 1997; 16:1202-8. [PMID: 9426952]
10. Bian ZM, Elner SG, Strieter RM, Kunkel SL, Lukacs NW, Elner
VM. IL-4 potentiates IL-1beta- and TNF-alpha-stimulated
IL-8 and MCP-1 protein production in human retinal pigment
epithelial  cells.  Curr  Eye  Res  1999;  18:349-57.  [PMID:
10372996]
11. Crane  IJ,  McKillop-Smith  S,  Wallace  CA,  Lamont  GR,
Forrester  JV.  Expression  of  the  chemokines  MIP-1alpha,
MCP-1, and RANTES in experimental autoimmune uveitis.
Invest  Ophthalmol  Vis  Sci  2001;  42:1547-52.  [PMID:
11381059]
12. Elner SG, Elner VM, Bian ZM, Lukacs NW, Kurtz RM, Strieter
RM,  Kunkel  SL.  Human  retinal  pigment  epithelial  cell
interleukin-8  and  monocyte  chemotactic  protein-1
modulation by T-lymphocyte products. Invest Ophthalmol
Vis Sci 1997; 38:446-55. [PMID: 9040478]
13. Elner VM, Burnstine MA, Strieter RM, Kunkel SL, Elner SG.
Cell-associated  human  retinal  pigment  epithelium
interleukin-8  and  monocyte  chemotactic  protein-1:
immunochemical and in-situ hybridization analyses. Exp Eye
Res 1997; 65:781-9. [PMID: 9441701]
14. Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S,
Hermann J, Ardjomand N, Haller-Schober EM, El-Shabrawi
Y. Role of the CCL2/MCP-1 −2518A>G gene polymorphism
in HLA-B27 associated uveitis. Mol Vis 2005; 11:896-900.
[PMID: 16280979]
15. Ahad MA, Missotten T, Abdallah A, Lympany PA, Lightman
S.  Polymorphisms  of  chemokine  and  chemokine  receptor
genes  in  idiopathic  immune-mediated  posterior  segment
uveitis. Mol Vis 2007; 13:388-96. [PMID: 17417600]
16. Chen Y, Vaughan RW, Kondeatis E, Fortune F, Graham EM,
Stanford MR, Wallace GR. Chemokine gene polymorphisms
associate with gender in patients with uveitis. Tissue Antigens
2004; 63:41-5. [PMID: 14651522]
17. Szalai C, Kozma GT, Nagy A, Bojszko A, Krikovszky D, Szabo
T, Falus A. Polymorphism in the gene regulatory region of
MCP-1 is associated with asthma susceptibility and severity.
J  Allergy  Clin  Immunol  2001;  108:375-81.  [PMID:
11544456]
18. Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M,
Szeimies RM, Müller-Ladner U, Schölmerich J, Hellerbrand
C. The -2518 promotor polymorphism in the MCP-1 gene is
associated with systemic sclerosis. J Invest Dermatol 2005;
124:92-8. [PMID: 15654958]
19. Rovin BH, Lu L, Saxena R. A novel polymorphism in the
MCP-1  gene  regulatory  region  that  influences  MCP-1
expression.  Biochem  Biophys  Res  Commun  1999;
259:344-8. [PMID: 10362511]
20. Read  RW,  Holland  GN,  Rao  NA,  Tabbara  KF,  Ohno  S,
Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M.
Revised  diagnostic  criteria  for  Vogt-Koyanagi-Harada
disease:  report  of  an  international  committee  on
nomenclature. Am J Ophthalmol 2001; 131:647-52. [PMID:
11336942]
21. Du L, Yang P, Hou S, Lin X, Zhou H, Huang X, Wang L,
Kijlstra  A.  Association  of  the  CTLA-4  gene  with  Vogt-
Koyanagi-Harada syndrome. Clin Immunol 2008; 127:43-8.
[PMID: 18282809]
22. Meng Q, Liu X, Yang P, Hou S, Du L, Zhou H, Kijlstra A.
PDCD1 genes may protect against extraocular manifestations
in  Chinese  Han  patients  with  Vogt-Koyanagi-Harada
syndrome. Mol Vis 2009; 15:386-92. [PMID: 19234630]
23. Horie Y, Takemoto Y, Miyazaki A, Namba K, Kase S, Yoshida
K, Ota M, Hasumi Y, Inoko H, Mizuki N, Ohno S. Tyrosinase
gene family and Vogt-Koyanagi-Harada disease in Japanese
patients. Mol Vis 2006; 12:1601-5. [PMID: 17200659]
24. Horie Y, Kitaichi N, Takemoto Y, Namba K, Yoshida K, Hirose
S,  Hasumi  Y,  Ota  M,  Inoko  H,  Mizuki  N,  Ohno  S.
Polymorphism  of  IFN-gamma  gene  and  Vogt-Koyanagi-
Harada  disease.  Mol  Vis  2007;  13:2334-8.  [PMID:
18199975]
25. Lima G, Soto-Vega E, Atisha-Fregoso Y, Sanchez-Guerrero J,
Vallejo M, Vargas-Alarcon G, Llorente L. MCP-1, RANTES,
and SDF-1 polymorphisms in Mexican patients with systemic
lupus erythematosus. Hum Immunol 2007; 68:980-5. [PMID:
18191726]
26. Gonzalez-Escribano MF, Torres B, Aguilar F, Rodriguez R,
Garcia A, Valenzuela A, Nunez-Roldan A. MCP-1 promoter
polymorphism in Spanish patients with rheumatoid arthritis.
Hum Immunol 2003; 64:741-4. [PMID: 12826377]
27. Li KS, Wang BY, Liu SY, Yao SP, Guo L, Mao DW. The
combination of polymorphisms within MCP-1 and IL-1beta
associated with ulcerative colitis. Int J Immunogenet 2009;
36:135-9. [PMID: 19392835]
28. Ozyurek AR, Gurses D, Ulger Z, Levent E, Bakiler AR, Berdeli
A.  Allelic  frequency  of  the  MCP-1  promoter  −2518
polymorphism  in  the  Turkish  population  and  in  Turkish
patients with juvenile rheumatoid arthritis. Clin Rheumatol
2007; 26:546-50. [PMID: 16835702]
29. Ye DQ, Hu YS, Li XP, Yang SG, Hao JH, Huang F, Zhang XJ.
The correlation between monocyte chemoattractant protein-1
and  the  arthritis  of  systemic  lupus  erythematosus  among
Chinese.  Arch  Dermatol  Res  2005;  296:366-71.  [PMID:
15611878]
Molecular Vision 2009; 15:1537-1541 <http://www.molvis.org/molvis/v15/a164> © 2009 Molecular Vision
1540Molecular Vision 2009; 15:1537-1541 <http://www.molvis.org/molvis/v15/a164> © 2009 Molecular Vision
The print version of this article was created on 5 August 2009. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1541